Literature DB >> 27166223

Impaired protein degradation in FTLD and related disorders.

Julia K Götzl1, Christina M Lang1, Christian Haass2, Anja Capell3.   

Abstract

Impaired protein degradation has been discussed as a cause or consequence of various neurodegenerative diseases, such as Alzheimer's, Parkinson's and Huntington's disease. More recently, evidence accumulated that dysfunctional protein degradation may play a role in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Since in almost all neurodegenerative diseases, protein aggregates are disease-defining hallmarks, it is most likely that impaired protein degradation contributes to disease onset and progression. In the majority of FTD cases, the pathological protein aggregates contain either microtubuleassociated protein tau or TAR DNA-binding protein (TDP)-43. Aggregates are also positive for ubiquitin and p62/sequestosome 1 (SQSTM1) indicating that these aggregates are targeted for degradation. FTD-linked mutations in genes encoding three autophagy adaptor proteins, p62/SQSTM1, ubiquilin 2 and optineurin, indicate that impaired autophagy might cause FTD. Furthermore, the strongest evidence for lysosomal impairment in FTD is provided by the progranulin (GRN) gene, which is linked to FTD and neuronal ceroid lipofuscinosis. In this review, we summarize the observations that have been made during the last years linking the accumulation of disease-associated proteins in FTD to impaired protein degradation pathways. In addition, we take resent findings for nucleocytoplasmic transport defects of TDP-43, as discussed for hexanucleotide repeat expansions in C9orf72 into account and provide a hypothesis how the interplay of altered nuclear transport and protein degradation leads to the accumulation of protein deposits. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autophagy-lysosome system; Frontotemporal lobar degeneration (FTLD); Neurodegeneration; Neuronal ceroid lipofuscinosis (NCL); TDP-43; Ubiquitin-proteasome system (UPS)

Mesh:

Substances:

Year:  2016        PMID: 27166223     DOI: 10.1016/j.arr.2016.04.008

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  33 in total

Review 1.  Lysosome trafficking and signaling in health and neurodegenerative diseases.

Authors:  Pearl P Y Lie; Ralph A Nixon
Journal:  Neurobiol Dis       Date:  2018-05-30       Impact factor: 5.996

2.  Biallelic SQSTM1 mutations in early-onset, variably progressive neurodegeneration.

Authors:  Valentina Muto; Elisabetta Flex; Zachary Kupchinsky; Guido Primiano; Hamid Galehdari; Mohammadreza Dehghani; Serena Cecchetti; Giovanna Carpentieri; Teresa Rizza; Neda Mazaheri; Alireza Sedaghat; Mohammad Yahya Vahidi Mehrjardi; Alice Traversa; Michela Di Nottia; Maria M Kousi; Yalda Jamshidi; Andrea Ciolfi; Viviana Caputo; Reza Azizi Malamiri; Francesca Pantaleoni; Simone Martinelli; Aaron R Jeffries; Jawaher Zeighami; Amir Sherafat; Daniela Di Giuda; Gholam Reza Shariati; Rosalba Carrozzo; Nicholas Katsanis; Reza Maroofian; Serenella Servidei; Marco Tartaglia
Journal:  Neurology       Date:  2018-06-29       Impact factor: 9.910

Review 3.  Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.

Authors:  Barry Boland; Wai Haung Yu; Olga Corti; Bertrand Mollereau; Alexandre Henriques; Erwan Bezard; Greg M Pastores; David C Rubinsztein; Ralph A Nixon; Michael R Duchen; Giovanna R Mallucci; Guido Kroemer; Beth Levine; Eeva-Liisa Eskelinen; Fanny Mochel; Michael Spedding; Caroline Louis; Olivier R Martin; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

4.  Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism.

Authors:  Julia K Götzl; Matthias Brendel; Georg Werner; Samira Parhizkar; Laura Sebastian Monasor; Gernot Kleinberger; Alessio-Vittorio Colombo; Maximilian Deussing; Matias Wagner; Juliane Winkelmann; Janine Diehl-Schmid; Johannes Levin; Katrin Fellerer; Anika Reifschneider; Sebastian Bultmann; Peter Bartenstein; Axel Rominger; Sabina Tahirovic; Scott T Smith; Charlotte Madore; Oleg Butovsky; Anja Capell; Christian Haass
Journal:  EMBO Mol Med       Date:  2019-06       Impact factor: 12.137

Review 5.  Neuronal Cell Death.

Authors:  Michael Fricker; Aviva M Tolkovsky; Vilmante Borutaite; Michael Coleman; Guy C Brown
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 6.  TDP-43 in the spectrum of MND-FTLD pathologies.

Authors:  Lanier Heyburn; Charbel E-H Moussa
Journal:  Mol Cell Neurosci       Date:  2017-07-04       Impact factor: 4.314

Review 7.  The roles of intrinsic disorder-based liquid-liquid phase transitions in the "Dr. Jekyll-Mr. Hyde" behavior of proteins involved in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

Authors:  Vladimir N Uversky
Journal:  Autophagy       Date:  2017-12-17       Impact factor: 16.016

8.  Rare variants in the neuronal ceroid lipofuscinosis gene MFSD8 are candidate risk factors for frontotemporal dementia.

Authors:  Ethan G Geier; Mathieu Bourdenx; Nadia J Storm; J Nicholas Cochran; Daniel W Sirkis; Ji-Hye Hwang; Luke W Bonham; Eliana Marisa Ramos; Antonio Diaz; Victoria Van Berlo; Deepika Dokuru; Alissa L Nana; Anna Karydas; Maureen E Balestra; Yadong Huang; Silvia P Russo; Salvatore Spina; Lea T Grinberg; William W Seeley; Richard M Myers; Bruce L Miller; Giovanni Coppola; Suzee E Lee; Ana Maria Cuervo; Jennifer S Yokoyama
Journal:  Acta Neuropathol       Date:  2018-10-31       Impact factor: 17.088

Review 9.  Lysosomal Dysfunction at the Centre of Parkinson's Disease and Frontotemporal Dementia/Amyotrophic Lateral Sclerosis.

Authors:  Rebecca L Wallings; Stewart W Humble; Michael E Ward; Richard Wade-Martins
Journal:  Trends Neurosci       Date:  2019-11-05       Impact factor: 13.837

10.  Trends in Understanding the Pathological Roles of TDP-43 and FUS Proteins.

Authors:  Emanuele Buratti
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.